Diabetic macular edema eye drop from Oculis fails to meet primary endpoint

Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary endpoint in a phase 3 program, according to a press release.The DIAMOND program included two phase 3 trials that evaluated OCS-01 (dexamethasone 15 mg/mL) in more than 800 patients with DME. Both trials, DIAMOND-1 and DIAMOND-2, failed to meet their primary endpoint of mean

Raccontata daendpoints.newsbenzinga.comhealio.com